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A cutting-edge ‘genome sequencer’, 
the first of its kind in Africa, was set 
up in Pretoria this March, slashing 
vital research result times from a year 
to 2 days and helping local scientists 
pinpoint causes for dangerous drug 
resistances such as in TB.
The R6 million high-tech instrument 
will almost certainly save lives 
by providing new avenues for 
diagnostic advances in medicine and 
biotechnology, according to Dr Oliver 
Preisig, CEO of the private South 
African genomics company inqaba 
biotec (www.inqababiotec.co.za).
For example, it can sequence the 
whole genome of various TB strains, 
enabling researchers to pinpoint which 
difference is responsible for the new 
phenotype creating the antibiotic 
resistance. Using this information, 
scientists can design a simple 
diagnostics test that can be used in the 
laboratory to identify the TB strain, 
enabling them either to develop or use 
more accurate, appropriate and effective 
antibiotics.
Solves ‘enduring mysteries’
It may well contribute to solving 
the enduring enigma of the XDR TB 
outbreak at Tugela Ferry in KwaZulu-
Natal last year when XDR cases 
uniquely outnumbered MDR cases 
– with nation-wide implications for vital 
TB prevention.
Besides the speed with which local 
geneticists can now look forward to 
results (the current ‘GS20’ system will 
be upgraded to the more powerful 
GS FLX later this month, reducing the 
genome sequencing of a bacterium from 
a week to 2 days), the new equipment 
will cut costs from on average R1.5 
million per genome to R200 000.
Preisig said local universities, the 
CSIR and the MRC were showing ‘great 
interest’.
‘We’re not here to make money 
with this sequencer – the exposure is 
much more important for us, though 
obviously it needs to be sustainable 
and carry the costs of insurance, 
maintenance, involved personnel and 
repeats of failed runs,’ he said.
Inqaba biotec has teamed up with 
BioPAD (Department of Science 
and Technology), a state-funded 
biotechnology trust  aimed at brokering 
partnerships to help South Africa 
obtain an effective mix of technical and 
business expertise in biotechnology and 
benefit the entire region. Preisig said the 
machine was able to look for mutations, 
say from cancer cells, at uniquely low 
percentages of occurrence.
Going ‘deeper’ than ever before
Until recently traditional sequencers 
based on the Sanger method were only 
able to look for mutations occurring 
at a frequency of above 20%. The new 
genome sequencer can probe ‘ultra 
deep’ to frequencies of as low as 5%. ‘At 
the end of the day, what you get out of 
it is simply amazing,’ Preisig said.
Genome sequencing can 
show a predisposition 
to a variety of illnesses, 
including breast cancer, 
disorders of haemostasis 
and liver disease and was 
previously only done at 
large sequencing centres 
overseas, taking more than 
a year.
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Dr Oliver Preisig ( left), CEO inqaba biotec, and Arshad Ismail, GS Manager, inqaba biotec.
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Since the first genome sequencer was 
installed in March this year, inqaba 
biotec had sequenced the genome of 
a plant pathogenic bacterium and at 
the time of writing had mycoplasma, 
thermophilic bacterial and a viral 
(veterinary) genome lined up.
‘Because we’re a private company 
with links to all the universities as a 
service provider, each institution can 
use us, rather than compete against one 
another with individual machines,’ he 
added.
Genome sequencing can show a 
predisposition to a variety of illnesses, 
including breast cancer, disorders of 
haemostasis and liver disease and 
was previously only done at large 
sequencing centres overseas, taking 
more than a year. The local machine 
can perform sequencing runs more 
than 60 times faster than conventional 
commercially available platforms.
A counter to rapid disease spread
Asked why speed was so important, 
Preisig said that with today’s mobility 
having shrunk the globe, it was easier 
for new strains of pathogens, such as 
drug-resistant TB, to ‘wreak havoc’ in a 
much shorter time.
‘The ability to sequence a whole 
genome at reasonable cost means 
that causes for drug resistance can 
be pinpointed easily,’ he added. The 
technology's sensitivity in detecting 
rare cell mutations also promotes 
the possibility of much earlier cancer 
identification.
Comparing the genome sequences 
of two or more individuals of the 
same species can also provide clues to 
the reason for difference and explain 
why one individual is more prone 
to a disease than another.  The GS 
technology can provide many more 
genome sequences to compare with 
one another and find ‘differences that 
matter’.
Said Preisig: ‘If we look back, we can 
analyse DNA from fossils with the aim 
of resolving evolutionary questions like 
the current groundbreaking discoveries 
with regard to sequencing of the 
Neanderthal.’ The company’s name 
inqaba  means ‘rare and precious’ in 
Xhosa. It was initiated and funded by a 
handful of scientists from South Africa, 
the USA, Germany and Switzerland.
Preisig, who is Swiss-born, said 
a Swiss government loan aimed at 
facilitating investments in developing 
and emerging countries played a 
‘crucial part’ in the start-up years of the 
company.
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